New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study

Once‐daily deferasirox dispersible tablets (DT) have a well‐defined safety and efficacy profile and, compared with parenteral deferoxamine, provide greater patient adherence, satisfaction, and quality of life. However, barriers still exist to optimal adherence, including gastrointestinal tolerabilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Taher, Ali T., Origa, Raffaella, Perrotta, Silverio, Kourakli, Alexandra, Ruffo, Giovan Battista, Kattamis, Antonis, Goh, Ai‐Sim, Cortoos, Annelore, Huang, Vicky, Weill, Marine, Merino Herranz, Raquel, Porter, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585741/
https://www.ncbi.nlm.nih.gov/pubmed/28142202
http://dx.doi.org/10.1002/ajh.24668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585741/
https://www.ncbi.nlm.nih.gov/pubmed/28142202
http://dx.doi.org/10.1002/ajh.24668

Ejemplares similares